X
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
https://pharmaphorum.com/news/novartis-lucentis-could-face-biosimilar-competition/
Samsung Bioepis
Samsung Bioepis and Takeda begin first trial from R&D tie-up
Companies signed risk-sharing deal last year
Biogen gets go-ahead for EU Humira launch in October
But deal with Samsung prevents US launch until mid-2023
Samsung Bioepis Herceptin biosimilar approved in EU
Mylan and Biocon resolve biosimilar manufacturing issues
Ready to pounce: Samsung joins Amgen with Humira biosimilar approval
No-one can launch biosimilars until patent expires next year
Samsung Bioepis signs R&D agreement with Takeda
South Korean firm looking to develop novel drugs
1 2